Global Leishmaniasis Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Leishmaniasis Market was valued at $380 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 3.2% CAGR, to an estimated market size of $445 mn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global leishmaniasis market encompasses the pharmaceutical treatments, diagnostic solutions, and clinical management of infections caused by the Leishmania genus of protozoan parasites. The scope includes therapies for the three primary clinical forms: cutaneous, mucocutaneous, and visceral (systemic) leishmaniasis, while excluding general vector control pesticides not specifically formulated for medical intervention.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Leishmaniasis Market in the period 2025-30:
- The expansion of sandfly habitats driven by climate change and global warming is increasing the geographic range of the disease into previously non-endemic regions.
- There is a significant therapeutic shift toward oral combination therapies and shorter-course regimens to replace toxic and invasive injectable antimonial treatments.
- Increased adoption of Liposomal Amphotericin B (AmBisome) is occurring due to its superior safety profile and reduced nephrotoxicity compared to traditional formulations.
- Rising drug resistance to first-line pentavalent antimonials, particularly in the Indian subcontinent, is necessitating the urgent development of novel chemical entities.
- The proliferation of Public-Private Partnerships involving organizations like the DNDi and the Bill & Melinda Gates Foundation is stabilizing drug pricing and supply chains in endemic countries.
- Advancements in rapid diagnostic tests (RDTs), such as rK39 dipsticks, are enabling earlier detection and treatment initiation in resource-limited rural settings.
- Growing interest in non-pharmacological interventions, including cryotherapy and localized thermotherapy, is providing alternative options for localized cutaneous cases.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Asia-Pacific
- Europe
- Rest of World
Segments
- Visceral Leishmaniasis
- Cutaneous Leishmaniasis
- Mucocutaneous Leishmaniasis